The latent variable “δ” (for “dementia) is a transdiagnostic measure of dementia severity. δ can be reified and applied to individuals as a composite “d-score”. Like Spearman’s general intelligence factor “g”, δ can be constructed from almost any cognitive battery. So many are available that we must further distinguish each composite as a δ “homolog”. Fourteen have been validated. All are strongly associated with dementia severity and potentially with mild cognitive impairment (MCI) conversion.
Objectives:
To assess δ’s impact on MCI conversion risk.
Methods:
A new δ homolog (dDx) was constructed in 1,230 Mexican-American (MA) and 2,215 non-Hispanic White (NHW) participants in the Texas Alzheimer’s Research and Care Consortium (TARCC). 1,445 normal controls (NC) and 723 MCI were followed annually for up to 6 years.
Results:
Each SD decrease in the dDx score increased the risk of conversion sixteen-fold [OR = 16.39 (CI: 5.0–52.6)]. Cases below the optimal diagnostic threshold for Alzheimer’s disease (AD) versus NC were labeled as having a functionally salient cognitive impairment (FSCI). Such cases were at a 73-fold increase risk of a diagnosis of AD [OR = 73.19 (95% CI: 58.3–92.0)]. However, 25.6% of MCI cases were also FSCI(+). They accounted disproportionately for prospective conversions. Age <80 years, the absence of an ɛ4 allele, <12 years of education, and MA ethnicity independently increased the risk of diagnosing FSCI as MCI.
Conclusion:
A sizable minority of MCI cases may be misdiagnosed and they account disproportionately for AD conversions.
RoyallDR, PalmerRF, O’BryantSE (2012) Validation of a latent variable representing the dementing process. J Alzheimers Dis30, 639–649.
2.
SpearmanC (1904) General intelligence, objectively determined and measured. Am J Psychol15, 201–293.
3.
RoyallDR, PalmerRF (2014) “Executive functions” cannot be distinguished from general intelligence: Two variations on a single theme within a symphony of latent variance. Front Behav Neurosci9, 1–10.
4.
LawtonMP, BrodyEM (1969) Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist9, 179–186.
5.
GavettBE, VudyV, JeffreyM, JohnSE, GurnaniA, AdamsJ (2015) The δ latent dementia phenotype in the NACC UDS: Cross-validation and extension. Neuropsychology29, 344–352.
6.
JohnSE, GurnaniAS, BussellC, SaurmanJL (2016) The effectiveness and unique contribution of neuropsychological tests and the δ latent phenotype in the differential diagnosis of dementia in the Uniform Data Set. Neuropsychology30, 946–960.
7.
RoyallDR, Al-RubayeS, BishnoiR, PalmerRF (2016) Serum protein mediators of dementia and Aging proper. Aging8, 3241–3254.
8.
RoyallDR, Al-RubayeS, BishnoiR, PalmerRF (2017) Few serum proteins mediate APOE’s association with dementia. PLoS One12, e0172268.
9.
RoyallDR, Al-RubayeS, BishnoiR, PalmerRF (2017) Serum protein mediators of depression’s association with dementia. PLoS One12, e0175790.
JakAJ, BangenKJ, WierengaCE, Delano-WoodL, Corey-BloomJ, BondiMW (2009) Contributions of neuropsychology and neuroimaging to understanding clinical subtypes of mild cognitive impairment. Int Rev Neurobiol4, 81–103.
DipasqualeO, CercignaniM (2016) Network functional connectivity and whole-brain functional connectomics to investigate cognitive decline in neurodegenerative conditions. Funct Neurol31, 191–203.
15.
RozziniL, ChiloviBV, ContiM, BertolettiE, DelrioI, TrabucchiM, PadovaniA (2007) Conversion of amnestic mild cognitive impairment to dementia of Alzheimer type is independent to memory deterioration. Int J Geriatr Psychiatry22, 1217–1222.
TabertMH, ManlyJJ, LiuX, PeltonGH, RosenblumS, JacobsM, ZamoraD, GoodkindM, BellK, SternY, DevanandDP (2006) Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatr63, 916–924.
19.
HessenE, ReinvangI, EliassenCF, NordlundA, GjerstadL, FladbyT, WallinA (2014) The combination of dysexecutive and amnestic deficits strongly predicts conversion to dementia in young mild cognitive impairment cases. Dement Geriatr Cogn Disord Extra4, 76–85.
20.
LindberghCA, DishmanRK, MillerLS (2016) Functional disability in mild cognitive impairment: A systematic review and meta-analysis. Neuropsychol Rev26, 129–159.
21.
LuckT, LuppaM, WeiseB, MaierW, van den BusscheH, EiseleM, JessenF, WeegD, WeyererS, PentzekM, LeichtH, KoehlerM, TebarthF, OlbrichJ, Eifflaender-GorferS, FuchsA, KoenigHH, Reidel-HellerSG; AgeCoDe Study Group (2012) Prediction of incident dementia: Impact of impairment in instrumental activities of daily living and mild cognitive impairment-results from the German study on aging, cognition and dementia in primary care patients. Am J Geriatr Psychiatry20, 943–954.
22.
KopparaA, WolfsgruberS, KleineidamL, SchmidtkeK, FrölichL, KurzA, SchulzS, HampelH, HeuserI, PetersO, ReischiesFM, JahnH, LuckhausC, HüllM, GertzH-J, SchröderJ, PantelJ, RienhoffO, RütherE, HennF, WiltfangJ, MaierW, JessenF, KornhuberJ, WagnerM (2016) The latent dementia phenotype δ is associated with cerebrospinal fluid biomarkers of Alzheimer’s disease and predicts conversion to dementia in subjects with mild cognitive impairment. J Alzheimers Dis49, 547–560.
23.
RoyallDR, PalmerRF (2017) δ scores predict MCI and AD conversions from non-demented states. Alzheimers Dement (Amst)6, 214–221.
24.
PalmerRF, RoyallDR (2016) Future dementia status is almost entirely explained by the latent variable δ’s intercept and slope. J Alzheimers Dis49, 521–529.
25.
McKhannD, DrockmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group. Neurology34, 939–944.
26.
WitteMM, TrzepaczP, CaseM, YuP, HochstetlerH, QuinlivanM, SundellK, HenleyD (2014) Association between clinical measures and florbetapir F18 PET neuroimaging in mild or moderate Alzheimer’s disease dementia. J Neuropsychiatry Clin Neurosci26, 214–220.
27.
DegenhardtEK, WitteMM, CaseMG, YuP, HenleyDB, HochstetlerHM, D’SouzaDN, TrzepaczPT (2016) Florbetapir F18 PET amyloid neuroimaging and characteristics in patients with mild and moderate Alzheimer dementia. Psychosomatics57, 208–216.
28.
Hughes, CP, BergL, DanzigerWL, CobenLA, MartinRL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry140, 566–572.
29.
YesavageJA, BrinkTL, RoseTL, LumO, HuangV, AdeyM, LeirerVO (1982-1983) Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res17, 37–49.
30.
MitchellAJ, BirdV, RizzoM, MeaderN (2010) Which version of the Geriatric Depression Scale is most useful in medical settings and nursing homes? Diagnostic validity meta-analysis. Am J Geriatr Psychiatry18, 1066–1077.
31.
FolsteinMF, FolsteinSE, McHughPR (1975) Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res12, 189–198.
32.
Wechsler D (1997) Wechsler Memory Scale – Third Edition. The Psychological Corporation, San Antonio, TX.
33.
MorrisJC, Heyman, A, MohsRC, HughesJP, vanBelleG, FullenbaumG, HeymanA (1989) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology39, 1159–1165.
34.
Benton A, Hamsher K (1989) Multilingual Aphasia Examination. AJA Associates, Iowa City, Iowa.
35.
ReitanRM (1958) Validity of the Trail Making test as an indicator of organic brain damage. Percept Mot Skills8, 271–276.
GroschMS, ParikhMR, GrahamLL, HynanLS, WeinerMF, CullumC (2012) A new, quick, and cost-effective coding test: The Texas Assessment of Processing Speed (TAPS) [Abstract]. J Int Neuropsychol Soc18(Suppl S1), 71.
38.
Arbuckle, JL (2006) Analysis of Moment Structures-AMOS (Version 25.0) [Computer Program], SPSS, Chicago.
39.
GriceJW (2001) Computing and evaluation factor scores. Psychol Methods6, 430–450.
40.
Abd ElHafeezS, TorinoC, D’ArrigoG, BolignanoD, ProvenzanoF, Mattace-RasoF, ZoccaliC, TripepiG (2012) An overview on standard statistical methods for assessing exposure-outcome link in survival analysis (Part II): The Kaplan-Meier analysis and the Cox regression method. Aging Clin Exp Res24, 203–206.
41.
(2009) PASW Statistics 18, Release Version 18.0.0, SPSS, Inc. Chicago, IL.
42.
MetzCE (1978) Basic principles of ROC analysis. Sem Nuc Med8, 283–298.
43.
ZweigMH, CampbellG (1993) Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem39, 561–577.
44.
RocaM, ManesF, GleichgerrchtE, WatsonP, IbáñezA, ThompsonR, TorralvaT, DuncanJ (2013) Intelligence and executive functions in frontotemporal dementia. Neuropsychologia51, 725–730.
45.
MiyakeA, FriedmanNP, EmersonMJ, WitzkiAH, HowerterA, WagerTD (2000) The unity and diversity of executive functions and their contributions to complex “frontal lobe” tasks: A latent variable analysis. Cogn Psychol41, 49–100.
46.
FreidmanNP, MiyakeA (2017) Unity and diversity of executive functions: Individual differences as a window on cognitive structure. Cortex86, 186–204.
47.
BrodatyH, HeffernanM, KochanNA, DraperB, TrollorJN, ReppermundS, SlavinMJ, SachdevPS (2013) Mild cognitive impairment in a community sample: The Sydney Memory and Ageing Study. Alzheimer Dement9, 310–317.
48.
EllendtS, Voβ B, KohnN, WagelsL, GoerlichKS, DrexlerE, SchneiderF, HabelU (2017) Predicting stability of mild cognitive impairment (MCI): Findings of a community based sample. Curr Alzheimer Res14, 608–619.
49.
LuckT, LuppaM, AngermeyerMC, VillringerA, KöenigHH, Reidel-HellerSG (2011) Impact of impairment in instrumental activities of daily living and mild cognitive impairment on time to incident dementia: Results of the Leipzig Longitudinal Study of the Aged. Psychol Med41, 1087–1097.
50.
LindbergCA, DishmanRK, MillerLS (2016) Functional disability in mild cognitive impairment: A systematic review and meta-analysis. Neuropsychol Rev26, 129–159.
51.
RoyallDR, PalmerRF, MatsuokaT, KatoY, TaniguchiS, OgawaM, FujimotoH, OkamuraA, ShibataK, NakamuraK, NakaakiS, KoumiH, MimuraM, FukuiK, NarumotoJ (2016) Greater than the sum of its parts: δ scores are exportable across cultural and linguistic boundaries. J Alzheimers Dis49, 561–570.
RoyallDR, PalmerRF (2016) Thrombopoietin is associated with δ‘s intercept, and only in Non-Hispanic Whites. Alzheimers Dement (Amst)3, 35–42.
54.
RoyallDR, PalmerRF, MarkidesKS (2017) Exportation and validation of latent constructs for dementia case-finding in a Mexican-American population-based cohort. J Gerontol B Psychol Sci Soc Sci72, 947–955.
55.
RoyallDR, PalmerRF, MatsuokaT, KatoY, TaniguchiS, OgawaM, FujimotoH, OkamuraA, ShibataK, NakamuraK, NakaakiS, KoumiH, MimuraM, FukuiK, NarumotoJ (2016) Greater than the sum of its parts: δ can be constructed from item level data. J Alzheimers Dis49, 571–579.
56.
RoyallDR, PalmerRF (2018) Construction of a potential telephone assessment of dementia prevalence and severity. J Neuropsychiatry Clin Neurosci30, 202–207.
